Likewise, individual composite outcomes and secondary outcomes demonstrated no statistically significant differences. Treatment failure occurred in 15 patients (7.4%), with no statistically significant differences between groups. The majority of patients received a FQ (136 66.7%), followed by a BL (46 22.5%) and SXT (22 10.8%). Categorical endpoints were analysed using χ 2 test or Fisher's exact test, whilst continuous variables were assessed by one-way ANOVA.Ī total of 204 patients were included in the analysis. Additional endpoints included secondary infections and individual components within the primary endpoint. The composite primary endpoint was treatment failure, including 30-day mortality, recurrent bacteraemia or transition back to i.v. Patients were divided into one of three oral antibiotic treatment groups: FQ BL or SXT. The purpose of this study was to compare treatment of GNBSIs across three different oral antibiotic classes.Ī retrospective cohort of hospitalised patients with GNBSI receiving initial intravenous (i.v.) antibiotic therapy followed by step-down oral therapy was conducted. Currently, limited data exist evaluating treatment with β-lactams (BLs) or trimethoprim/sulfamethoxazole (SXT). To date, small trials have supported the use of specific classes of antibiotics, primarily fluoroquinolones (FQs), in the treatment of Gram-negative bloodstream infections (GNBSIs). Treatment of bacteraemia with oral antibiotics has the potential to reduce hospital length of stay, treatment costs and line-related complications.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |